OKYO Pharma to Present Positive Phase 2 Urcosimod Data for Neuropathic Corneal Pain at Major Scientific Conferences

summarizeSummary

OKYO Pharma announced its CEO and CSO will present at upcoming scientific conferences, with the CSO detailing positive Phase 2 data for Urcosimod in neuropathic corneal pain.

check_boxKey Events

• CEO to Present at Eyecelerator

  Robert J. Dempsey, CEO, will present on 'Addressing Unmet Needs in Corneal and Anterior Segment Diseases' at Eyecelerator on May 1, 2026.

• CSO to Present Positive Phase 2 Urcosimod Data at ARVO

  Raj Patil, PhD, CSO, will present 'First-in-Human Study of Urcosimod to Treat Neuropathic Corneal Pain (NCP) Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improvement in NCP Patients' at the ARVO Annual Meeting on May 5, 2026.

• Urcosimod Status and Future Plans

  Urcosimod (formerly OK-101) is the first investigational therapy with an IND specifically for NCP and has Fast Track designation. The company plans to initiate a 150-patient Phase 2b/3 multiple-dose study for Urcosimod in NCP in the first half of this year.

auto_awesomeAnalysis

This filing highlights OKYO Pharma's progress with its lead drug candidate, Urcosimod, by announcing presentations at two significant ophthalmology conferences. The Chief Scientific Officer's presentation at the ARVO Annual Meeting will detail positive Phase 2 data showing clinically meaningful pain reduction and quality-of-life improvement in patients with neuropathic corneal pain (NCP). This re-emphasizes previously announced positive results and provides further validation and visibility for Urcosimod, which has Fast Track designation and addresses a condition with no FDA-approved therapies. For a clinical-stage biopharmaceutical company, especially one that previously issued a 'going concern' warning, the continued positive development and public dissemination of clinical trial data are critical for investor confidence and future financing prospects. The planned initiation of a Phase 2b/3 study further signals advancement towards commercialization.